Immunovant, Inc. (IMVT)
IMVT Stock Price Chart
Explore Immunovant, Inc. interactive price chart. Choose custom timeframes to analyze IMVT price movements and trends.
IMVT Company Profile
Discover essential business fundamentals and corporate details for Immunovant, Inc. (IMVT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Jun 2019
Employees
362.00
Website
https://immunovant.comCEO
Eric Venker
Description
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
IMVT Financial Timeline
Browse a chronological timeline of Immunovant, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.66.
Earnings released on 20 May 2026
EPS came in at -$0.73 falling short of the estimated -$0.59 by -23.31%.
Earnings released on 6 Feb 2026
EPS came in at -$0.61 surpassing the estimated -$0.72 by +15.28%.
Earnings released on 10 Nov 2025
EPS came in at -$0.73 falling short of the estimated -$0.72 by -1.39%.
Earnings released on 11 Aug 2025
EPS came in at -$0.60 surpassing the estimated -$0.69 by +13.04%.
Earnings released on 29 May 2025
EPS came in at -$0.64 surpassing the estimated -$0.71 by +10.27%.
Earnings released on 6 Feb 2025
EPS came in at -$0.76 falling short of the estimated -$0.73 by -4.11%.
Earnings released on 7 Nov 2024
EPS came in at -$0.74 falling short of the estimated -$0.61 by -21.31%.
Earnings released on 6 Aug 2024
EPS came in at -$0.60 falling short of the estimated -$0.53 by -13.21%.
Earnings released on 29 May 2024
EPS came in at -$0.52 falling short of the estimated -$0.43 by -20.93%.
Earnings released on 12 Feb 2024
EPS came in at -$0.36 surpassing the estimated -$0.43 by +16.28%.
Earnings released on 9 Nov 2023
EPS came in at -$0.45 surpassing the estimated -$0.47 by +4.26%.
Earnings released on 10 Aug 2023
EPS came in at -$0.57 falling short of the estimated -$0.45 by -26.67%.
Earnings released on 22 May 2023
EPS came in at -$0.46 falling short of the estimated -$0.43 by -6.98%.
Earnings released on 3 Feb 2023
EPS came in at -$0.49 falling short of the estimated -$0.39 by -25.64%.
Earnings released on 4 Nov 2022
EPS came in at -$0.41 falling short of the estimated -$0.39 by -5.13%.
Earnings released on 5 Aug 2022
EPS came in at -$0.35 surpassing the estimated -$0.40 by +12.50%.
Earnings released on 8 Jun 2022
EPS came in at -$0.41 falling short of the estimated -$0.38 by -7.89%.
Earnings released on 4 Feb 2022
EPS came in at -$0.36 falling short of the estimated -$0.33 by -9.09%.
Earnings released on 5 Nov 2021
EPS came in at -$0.35 falling short of the estimated -$0.28 by -25.00%.
Earnings released on 9 Aug 2021
EPS came in at -$0.31 matching the estimated -$0.31.
IMVT Stock Performance
Access detailed IMVT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
